28657-39-8

Basic information

• Product Name: 3-chloro-4-methyl-6-phenylpyridazine
• Synonyms: 3-chloro-4-methyl-6-phenylpyridazine
• CAS NO: 28657-39-8
• Molecular Formula: C₁₁H₉ClN₂
• Molecular Weight: 204.65556
• EINECS: 249-130-1
• Mol File: 28657-39-8.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 374.2°Cat760mmHg
• Flash Point: 211.9°C
• Appearance: /
• Density: 1.208g/cm³
• Vapor Pressure: 1.82E-05mmHg at 25°C
• Refractive Index: 1.584
• CAS DataBase Reference: 3-chloro-4-methyl-6-phenylpyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloro-4-methyl-6-phenylpyridazine(28657-39-8)
• EPA Substance Registry System: 3-chloro-4-methyl-6-phenylpyridazine(28657-39-8)

Safety Data

• Hazardous Substances Data: 28657-39-8(Hazardous Substances Data)

Usage

Description

3-Chloro-4-methyl-6-phenylpyridazine is a chemical compound that belongs to the pyridazine family. It is characterized by a molecular structure containing a pyridazine ring with a chlorine atom at the 3-position, a methyl group at the 4-position, and a phenyl group at the 6-position. 3-chloro-4-methyl-6-phenylpyridazine is often used as a building block in the synthesis of various pharmaceuticals and agrochemicals due to its unique structural features and potential biological activities.

Uses

Used in Pharmaceutical Industry:
3-Chloro-4-methyl-6-phenylpyridazine is used as a key intermediate in the synthesis of various pharmaceuticals for its potential biological activities. It serves as a valuable building block in the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
3-Chloro-4-methyl-6-phenylpyridazine is used as a precursor in the synthesis of agrochemicals, contributing to the development of novel pesticides and other agrochemical products with enhanced efficacy and selectivity.
Used in Medicinal Chemistry Research:
3-Chloro-4-methyl-6-phenylpyridazine is used as a research compound in medicinal chemistry to explore its potential as an antitumor agent and a potential inhibitor of certain enzymes. Its unique molecular structure and biological activities make it a promising candidate for further investigation and development in the field of drug discovery.

InChI:InChI=1/C11H9ClN2/c1-8-7-10(13-14-11(8)12)9-5-3-2-4-6-9/h2-7H,1H3

Upstream product

• 13300-09-9 4-methyl-6-phenylpyridazin-3(2H)-one 
• 19064-64-3 3,6-dichloro-4-methylpyridazine 
• 98-80-6 phenylboronic acid 
• 10330-57-1 3-methoxy-4-methyl-6-phenylpyridazine 
• 4578-42-1 3-methoxy-6-phenylpyridazine 
• 1771-65-9 2-methyl-4-oxo-4-phenylbutanoic acid 
• 52239-91-5 4-methyl-6-phenyl-4,5-dihydropyridazin-3(2H)-one 
• 10025-87-3 trichlorophosphate 
• 75-91-2 tert.-butylhydroperoxide 
• 20375-65-9 3-chloro-6-phenylpyradazine 
• 75-07-0 acetaldehyde 

Downstream Products

• 25905-77-5 minaprine 
• 25905-57-1 (4-Methyl-6-phenyl-pyridazin-3-yl)-(3-morpholin-4-yl-propyl)-amine; hydrochloride 
• 81819-94-5 (4-Methyl-6-phenyl-pyridazin-3-yl)-(6-phenyl-pyridazin-3-yl)-amine 
• 955997-24-7 4-methyl-6-phenyl-3-(4-(pyridin-2-yl)piperazin-1-yl)pyridazine 
• 924909-75-1 TT-302 
• 86112-23-4 3-(2-METHOXY ETHYLAMINO)4-METHYL 6-PHENYL PYRIDAZINE (HYDROCHLORIDE) 
• 81820-01-1 4-methyl-6-phenyl-3-<10-(phenothiazinyl-5-sulphone)>pyridazine 
• 81819-92-3 3-<β-naphthylazo>-4-methyl-6-phenylpyridazine 
• 13300-09-9 4-methyl-6-phenylpyridazin-3(2H)-one 
• 105537-56-2 2-(carboxymethyl)-3-amino-4-methyl-6-phenylpyridazinium acetate 
• 105537-95-9 6-Amino-1-(3-ethoxycarbonyl-1-methyl-propyl)-5-methyl-3-phenyl-pyridazin-1-ium; bromide 
• 105537-93-7 ethyl ester of 2-(5-carboxypentyl)-3-amino-4-methyl-6-phenylpyridazinium bromide 
• 105537-94-8 6-Amino-1-(3-ethoxycarbonyl-butyl)-5-methyl-3-phenyl-pyridazin-1-ium; bromide 
• 105537-92-6 6-Amino-1-(4-ethoxycarbonyl-butyl)-5-methyl-3-phenyl-pyridazin-1-ium; bromide 

Relevant articles and documents

A new two-step procedure for functionalized-3(2H)-pyridazinones through homolytic substitution of 3-chloropyridazines

The homolytic substitution of protonated 3-chloro-6-methylpyridazine 1a, followed by hydrolysis with AcOH affords 4- or 4,5-functionalized pyridazinones 3a-c. Less reactivity is found for 3-chloro-6-phenylpyridazine 1b. Hypotheses about these different behaviour patterns are proposed and discussed.

FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS

The invention relates to chemical compounds, compositions and methods of making and using the same. In particular, the invention provides selected pyridazine compounds of the formula I are independently hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, sulfate, sulfenyl, sulfinyl, sulfonyl, sulfonate, sulfoxide, silyl, silyloxy, silylalkyl, silylthio, ═O, ═S, phosphonate, ureido, carboxyl, carbonyl, carbamoyl, or carboxamide; and X is optionally substituted pyrimidinyl or pyridazinyl, an isomer, a pharmaceutically acceptable salt, or derivative thereof. The invention additional relates to compositions comprising the compounds, and methods of using the compounds and compositions for modulation of cellular pathways, for treatment or prevention of inflammatory diseases, for research, drug screening, and therapeutic applications.

Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits

We report the development of a novel, aqueous-soluble, safe, small molecule, experimental therapeutic that suppresses injury-induced, proinflammatory cytokine increases in the brain, with resultant attenuation of synaptic protein biomarker loss and improvement in hippocampus-dependent behavioral deficits. A GMP production scheme for the active pharmaceutical ingredient, compound 17, is presented. The development and large-scale availability of this novel compound allow exploration of new, potentially disease-modifying, therapeutic approaches to CNS disorders.